CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 40 enrolled
Drug / intervention
Autologous Transfusion +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02684747
NCT02684747Early Ph 1Completed
CompareCT.gov

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

University of Utah·interventional·Posted Feb 18, 2016·Updated May 14, 2018

In Brief

A Early Phase 1 clinical trial evaluating Autologous Transfusion and Control - Normal Saline (Placebo) for Blood Transfusion, Autologous and Blood Doping. Completed, enrolled 40 participants across 1 site.

Detailed Summary

A total of 40 subjects will be recruited for participation in this study. 20 subjects (10 males and 10 females) will be randomized to the active group (those receiving re-infusion of autologous blood) and 20 subjects (10 males and 10 females) will be randomized to the placebo group (receiving NS infusion).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Transfusion, Autologous, Blood Doping
CountriesUnited States
CollaboratorsSports Medicine Research and Testing Laboratory, Partnership for Clean Competition

Timeline

Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 18, 2016
Enrollment StartFeb 1, 2016
Primary CompletionMay 5, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.4 years ago

Interventions

Autologous Transfusionother

Participants will receive autologous transfusion on Day 21

Control - Normal Saline (Placebo)other

Participants will receive saline on Day 21